{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:03:14Z","timestamp":1789675394850,"version":"4.0.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["7254401"],"award-info":[{"award-number":["7254401"]}]},{"name":"Basic Research Plan of Natural Science in Shaanxi Province of China","award":["2024JC-YBMS-661"],"award-info":[{"award-number":["2024JC-YBMS-661"]}]},{"name":"Clinical Research Award of the First Affiliated Hospital of Xi\u2019an Jiaotong University","award":["XJTU1AF-CRF-2023-032"],"award-info":[{"award-number":["XJTU1AF-CRF-2023-032"]}],"id":[{"id":"https:\/\/ror.org\/02tbvhh96","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Clinical Research Award of the First Affiliated Hospital of Xi\u2019an Jiaotong University","award":["XJTU1AF-CRF-2022-009"],"award-info":[{"award-number":["XJTU1AF-CRF-2022-009"]}],"id":[{"id":"https:\/\/ror.org\/02tbvhh96","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10495-026-02429-5","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:08:10Z","timestamp":1787227690000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disrupting KRAS\u2013AGO2 interaction: a dual-pronged strategy to sensitize chemo-immunotherapy in KRAS-mutated colorectal cancer"],"prefix":"10.1007","volume":"31","author":[{"given":"Jingyi","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7010-7944","authenticated-orcid":false,"given":"Peng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"issue":"3","key":"2429_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2429_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"2429_CR3","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","volume":"19","author":"SR Punekar","year":"2022","unstructured":"Punekar SR, Velcheti V, Neel BG, Wong KK (2022) The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol 19(10):637\u2013655","journal-title":"Nat Rev Clin Oncol"},{"key":"2429_CR4","unstructured":"Benson AB, Venook AP, Adam M, Chang G, Chen Y-J, Ciombor KK et al (2024) Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 22(2D):e240029"},{"issue":"1","key":"2429_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","volume":"20","author":"G Zhu","year":"2021","unstructured":"Zhu G, Pei L, Xia H, Tang Q, Bi F (2021) Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer 20(1):143","journal-title":"Mol Cancer"},{"issue":"17","key":"2429_CR6","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1158\/1078-0432.CCR-11-3210","volume":"18","author":"Y Imamura","year":"2012","unstructured":"Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M et al (2012) Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res 18(17):4753\u20134763","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2429_CR7","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/annonc\/mdw261","volume":"27","author":"DP Modest","year":"2016","unstructured":"Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R et al (2016) Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol 27(9):1746\u20131753","journal-title":"Ann Oncol"},{"key":"2429_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3389\/fgene.2015.00116","volume":"6","author":"DM Zocche","year":"2015","unstructured":"Zocche DM, Ramirez C, Fontao FM, Costa LD, Redal MA (2015) Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer. Front Genet 6:116","journal-title":"Front Genet"},{"issue":"1","key":"2429_CR9","doi-asserted-by":"publisher","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","volume":"11","author":"S Hamarsheh","year":"2020","unstructured":"Hamarsheh S, Gross O, Brummer T, Zeiser R (2020) Immune modulatory effects of oncogenic KRAS in cancer. Nat Commun 11(1):5439","journal-title":"Nat Commun"},{"issue":"11","key":"2429_CR10","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D (2011) RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 11(11):761\u2013774","journal-title":"Nat Rev Cancer"},{"issue":"6330","key":"2429_CR11","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1126\/science.aam7622","volume":"355","author":"B Papke","year":"2017","unstructured":"Papke B, Der CJ, Drugging RAS (2017) Know the enemy. Science 355(6330):1158\u20131163","journal-title":"Science"},{"issue":"1","key":"2429_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu DK, Nissley DV, McCormick F (2017) RAS proteins and their regulators in human disease. Cell 170(1):17\u201333","journal-title":"Cell"},{"issue":"1","key":"2429_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","volume":"63","author":"BA Lanman","year":"2020","unstructured":"Lanman BA, Allen JR, Allen JG, Amegadzie AK, Ashton KS, Booker SK et al (2020) Discovery of a covalent inhibitor of KRAS(G12C) (AMG 510) for the treatment of solid tumors. J Med Chem 63(1):52\u201365","journal-title":"J Med Chem"},{"issue":"7477","key":"2429_CR14","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM (2013) K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503(7477):548\u2013551","journal-title":"Nature"},{"issue":"1","key":"2429_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM et al (2020) The KRAS(G12C) Inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov 10(1):54\u201371","journal-title":"Cancer Discov"},{"issue":"3","key":"2429_CR16","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","volume":"172","author":"MR Janes","year":"2018","unstructured":"Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X et al (2018) Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell 172(3):578\u2013589 e17","journal-title":"Cell"},{"issue":"13","key":"2429_CR17","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI et al (2020) KRAS(G12C) Inhibition with sotorasib in advanced solid tumors. N Engl J Med 383(13):1207\u20131217","journal-title":"N Engl J Med"},{"issue":"7","key":"2429_CR18","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrg3462","volume":"14","author":"G Meister","year":"2013","unstructured":"Meister G (2013) Argonaute proteins: functional insights and emerging roles. Nat Rev Genet 14(7):447\u2013459","journal-title":"Nat Rev Genet"},{"issue":"6","key":"2429_CR19","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.cell.2007.10.032","volume":"131","author":"S Diederichs","year":"2007","unstructured":"Diederichs S, Haber DA (2007) Dual role for argonautes in microRNA processing and posttranscriptional regulation of MicroRNA expression. Cell 131(6):1097\u20131108","journal-title":"Cell"},{"issue":"3","key":"2429_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.trecan.2017.01.002","volume":"3","author":"Y Qu","year":"2017","unstructured":"Qu Y, Shi B, Hou P, Activated ERK (2017) An emerging player in miRNA downregulation. Trends Cancer 3(3):163\u2013165","journal-title":"Trends Cancer"},{"issue":"11","key":"2429_CR21","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2022.04.030","volume":"185","author":"Y Qi","year":"2022","unstructured":"Qi Y, Ding L, Zhang S, Yao S, Ong J, Li Y et al (2022) A plant immune protein enables broad antitumor response by rescuing microRNA deficiency. Cell 185(11):1888\u20131904 e24","journal-title":"Cell"},{"issue":"6","key":"2429_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nrc3932","volume":"15","author":"S Lin","year":"2015","unstructured":"Lin S, Gregory RI (2015) MicroRNA biogenesis pathways in cancer. Nat Rev Cancer 15(6):321\u2013333","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2429_CR23","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cell.2005.01.014","volume":"120","author":"SM Johnson","year":"2005","unstructured":"Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A et al (2005) RAS is regulated by the let-7 microRNA family. Cell 120(5):635\u2013647","journal-title":"Cell"},{"issue":"1","key":"2429_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41568-020-00306-0","volume":"21","author":"GJ Goodall","year":"2020","unstructured":"Goodall GJ, Wickramasinghe VO (2020) RNA in cancer. Nat Rev Cancer 21(1):22\u201336","journal-title":"Nat Rev Cancer"},{"key":"2429_CR25","doi-asserted-by":"crossref","unstructured":"Ma Y, Shen N, Wicha MS, Luo M (2021) The roles of the Let-7 family of microRNAs in the regulation of cancer stemness. Cells 10(9):2415","DOI":"10.3390\/cells10092415"},{"issue":"6","key":"2429_CR26","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.celrep.2016.01.034","volume":"14","author":"S Shankar","year":"2016","unstructured":"Shankar S, Pitchiaya S, Malik R, Kothari V, Hosono Y, Yocum AK et al (2016) KRAS engages AGO2 to enhance cellular transformation. Cell Rep 14(6):1448\u20131461","journal-title":"Cell Rep"},{"key":"2429_CR27","doi-asserted-by":"crossref","unstructured":"Xie J, Liu J, Zhao M, Li X, Wang Y, Zhao Y et al (2023) Disulfiram\/Cu kills and sensitizes BRAF-mutant thyroid cancer cells to BRAF kinase inhibitor by ROS-dependently relieving feedback activation of MAPK\/ERK and PI3K\/AKT pathways. Int J Mol Sci 24(4):3418","DOI":"10.3390\/ijms24043418"},{"issue":"8","key":"2429_CR28","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1038\/s41418-021-00762-7","volume":"28","author":"X Su","year":"2021","unstructured":"Su X, Feng C, Wang S, Shi L, Gu Q, Zhang H et al (2021) The noncoding RNAs SNORD50A and SNORD50B-mediated TRIM21-GMPS interaction promotes the growth of p53 wild-type breast cancers by degrading p53. Cell Death Differ 28(8):2450\u20132464","journal-title":"Cell Death Differ"},{"issue":"12","key":"2429_CR29","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1038\/nprot.2013.152","volume":"8","author":"JS Zheng","year":"2013","unstructured":"Zheng JS, Tang S, Qi YK, Wang ZP, Liu L (2013) Chemical synthesis of proteins using peptide hydrazides as thioester surrogates. Nat Protoc 8(12):2483\u20132495","journal-title":"Nat Protoc"},{"issue":"4","key":"2429_CR30","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.7150\/ijbs.105575","volume":"21","author":"M Yuan","year":"2025","unstructured":"Yuan M, Shi L, Liu Y, Xiang K, Zhang Y, Zhou Y et al (2025) Disulfiram\/copper triggers cGAS-STING innate immunity pathway via ROS-induced DNA damage that potentiates antitumor response to PD-1 checkpoint blockade. Int J Biol Sci 21(4):1730\u20131748","journal-title":"Int J Biol Sci"},{"issue":"10","key":"2429_CR31","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.tips.2021.07.001","volume":"42","author":"YS Zhu","year":"2021","unstructured":"Zhu YS, Tang K, Lv J (2021) Peptide-drug conjugate-based novel molecular drug delivery system in cancer. Trends Pharmacol Sci 42(10):857\u2013869","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"2429_CR32","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1039\/C1CS15237H","volume":"41","author":"EC Dreaden","year":"2012","unstructured":"Dreaden EC, Alkilany AM, Huang X, Murphy CJ, El-Sayed MA (2012) The golden age: gold nanoparticles for biomedicine. Chem Soc Rev 41(7):2740\u20132779","journal-title":"Chem Soc Rev"},{"issue":"1","key":"2429_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12951-018-0362-1","volume":"16","author":"K Kalimuthu","year":"2018","unstructured":"Kalimuthu K, Lubin BC, Bazylevich A, Gellerman G, Shpilberg O, Luboshits G et al (2018) Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells. J Nanobiotechnol 16(1):34","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"2429_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/joim.12237","volume":"276","author":"Y Li","year":"2014","unstructured":"Li Y, Casey SC, Felsher DW (2014) Inactivation of MYC reverses tumorigenesis. J Intern Med 276(1):52\u201360","journal-title":"J Intern Med"},{"issue":"1","key":"2429_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3722","volume":"15","author":"PE Czabotar","year":"2014","unstructured":"Czabotar PE, Lessene G, Strasser A, Adams JM (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15(1):49\u201363","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"2429_CR36","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/molecules13081551","volume":"13","author":"N Zhang","year":"2008","unstructured":"Zhang N, Yin Y, Xu SJ, Chen WS (2008) 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 13(8):1551\u20131569","journal-title":"Molecules"},{"issue":"28","key":"2429_CR37","doi-asserted-by":"publisher","first-page":"6345","DOI":"10.3748\/wjg.v22.i28.6345","volume":"22","author":"V Sforza","year":"2016","unstructured":"Sforza V, Martinelli E, Ciardiello F, Gambardella V, Napolitano S, Martini G et al (2016) Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol 22(28):6345\u20136361","journal-title":"World J Gastroenterol"},{"key":"2429_CR38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13045-015-0210-9","volume":"8","author":"S Wang","year":"2015","unstructured":"Wang S, Su X, Bai H, Zhao J, Duan J, An T et al (2015) Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation. J Hematol Oncol 8:127","journal-title":"J Hematol Oncol"},{"issue":"7","key":"2429_CR39","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1158\/1535-7163.MCT-08-0021","volume":"7","author":"O Kovalchuk","year":"2008","unstructured":"Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF et al (2008) Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7(7):2152\u20132159","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"2429_CR40","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1124\/dmd.120.000207","volume":"48","author":"JL Jilek","year":"2020","unstructured":"Jilek JL, Tu MJ, Zhang C, Yu AM (2020) Pharmacokinetic and pharmacodynamic factors contribute to synergism between Let-7c-5p and 5-fluorouracil in inhibiting hepatocellular carcinoma cell viability. Drug Metab Dispos 48(12):1257\u20131263","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"2429_CR41","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440\u2013446","journal-title":"Cancer Res"},{"key":"2429_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27\u201355","journal-title":"Adv Enzyme Regul"},{"issue":"3","key":"2429_CR43","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621\u2013681","journal-title":"Pharmacol Rev"},{"issue":"13","key":"2429_CR44","doi-asserted-by":"publisher","first-page":"7476","DOI":"10.1073\/pnas.120159197","volume":"97","author":"J Wijnholds","year":"2000","unstructured":"Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F et al (2000) Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A 97(13):7476\u20137481","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"39","key":"2429_CR45","doi-asserted-by":"publisher","first-page":"30069","DOI":"10.1074\/jbc.M005463200","volume":"275","author":"G Jedlitschky","year":"2000","unstructured":"Jedlitschky G, Burchell B, Keppler D (2000) The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 275(39):30069\u201330074","journal-title":"J Biol Chem"},{"issue":"1\u20132","key":"2429_CR46","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000178884","volume":"9","author":"W Hagmann","year":"2009","unstructured":"Hagmann W, Jesnowski R, Faissner R, Guo C, Lohr JM (2009) ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology 9(1\u20132):136\u2013144","journal-title":"Pancreatology"},{"issue":"5","key":"2429_CR47","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1158\/1535-7163.MCT-04-0291","volume":"4","author":"S Pratt","year":"2005","unstructured":"Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W 3rd, Dantzig AH (2005) The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 4(5):855\u2013863","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2429_CR48","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1124\/dmd.110.033613","volume":"39","author":"PK Nambaru","year":"2011","unstructured":"Nambaru PK, Hubner T, Kock K, Mews S, Grube M, Payen L et al (2011) Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil. Drug Metab Dispos 39(1):132\u2013139","journal-title":"Drug Metab Dispos"},{"issue":"7718","key":"2429_CR49","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","volume":"560","author":"G Chen","year":"2018","unstructured":"Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W et al (2018) Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560(7718):382\u2013386","journal-title":"Nature"},{"issue":"2","key":"2429_CR50","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/jcp.27172","volume":"234","author":"FK Dermani","year":"2019","unstructured":"Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R (2019) PD-1\/PD-L1 immune checkpoint: potential target for cancer therapy. J Cell Physiol 234(2):1313\u20131325","journal-title":"J Cell Physiol"},{"issue":"3","key":"2429_CR51","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00262-013-1503-x","volume":"63","author":"CJ Maine","year":"2014","unstructured":"Maine CJ, Aziz NH, Chatterjee J, Hayford C, Brewig N, Whilding L et al (2014) Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother 63(3):215\u2013224","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"2429_CR52","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2326-6066.CIR-18-0331","volume":"7","author":"Y Chen","year":"2019","unstructured":"Chen Y, Xie C, Zheng X, Nie X, Wang Z, Liu H et al (2019) LIN28\/let-7\/PD-L1 pathway as a target for cancer immunotherapy. Cancer Immunol Res 7(3):487\u2013497","journal-title":"Cancer Immunol Res"},{"key":"2429_CR53","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2020.06.023","volume":"137","author":"F Passiglia","year":"2020","unstructured":"Passiglia F, Malapelle U, Del Re M, Righi L, Pagni F, Furlan D et al (2020) KRAS inhibition in non-small cell lung cancer: past failures, new findings and upcoming challenges. Eur J Cancer 137:57\u201368","journal-title":"Eur J Cancer"},{"key":"2429_CR54","doi-asserted-by":"publisher","first-page":"101974","DOI":"10.1016\/j.ctrv.2020.101974","volume":"84","author":"M Nagasaka","year":"2020","unstructured":"Nagasaka M, Li Y, Sukari A, Ou SI, Al-Hallak MN, Azmi AS (2020) KRAS G12C game of thrones, which direct KRAS inhibitor will claim the iron throne? Cancer Treat Rev 84:101974","journal-title":"Cancer Treat Rev"},{"issue":"16","key":"2429_CR55","doi-asserted-by":"publisher","first-page":"e2100250","DOI":"10.1002\/advs.202100250","volume":"8","author":"B Zhang","year":"2021","unstructured":"Zhang B, Zhang Y, Zhang J, Liu P, Jiao B, Wang Z et al (2021) Focal adhesion kinase (FAK) inhibition synergizes with KRAS G12C inhibitors in treating cancer through the regulation of the FAK-YAP signaling. Adv Sci (Weinh) 8(16):e2100250","journal-title":"Adv Sci (Weinh)"},{"issue":"9","key":"2429_CR56","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s43018-024-00800-6","volume":"5","author":"V Thatikonda","year":"2024","unstructured":"Thatikonda V, Lyu H, Jurado S, Kostyrko K, Bristow CA, Albrecht C et al (2024) Co-targeting SOS1 enhances the antitumor effects of KRAS(G12C) inhibitors by addressing intrinsic and acquired resistance. Nat Cancer 5(9):1352\u20131370","journal-title":"Nat Cancer"},{"issue":"7782","key":"2429_CR57","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM (2019) A view on drug resistance in cancer. Nature 575(7782):299\u2013309","journal-title":"Nature"},{"issue":"4","key":"2429_CR58","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1023\/A:1006416410198","volume":"18","author":"JL Grem","year":"2000","unstructured":"Grem JL (2000) 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 18(4):299\u2013313","journal-title":"Invest New Drugs"},{"issue":"1","key":"2429_CR59","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","volume":"18","author":"S Giacchetti","year":"2000","unstructured":"Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18(1):136\u2013147","journal-title":"J Clin Oncol"},{"issue":"9209","key":"2429_CR60","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209):1041\u20131047","journal-title":"Lancet"},{"issue":"6","key":"2429_CR61","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1200\/JCO.2008.19.5362","volume":"27","author":"D Sargent","year":"2009","unstructured":"Sargent D, Sobrero A, Grothey A, O\u2019Connell MJ, Buyse M, Andre T et al (2009) Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 27(6):872\u2013877","journal-title":"J Clin Oncol"},{"issue":"8","key":"2429_CR62","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17(8):807\u2013821","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"2429_CR63","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD (2020) Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37(4):443\u2013455","journal-title":"Cancer Cell"},{"issue":"5","key":"2429_CR64","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","volume":"25","author":"M Roerden","year":"2025","unstructured":"Roerden M, Spranger S (2025) Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat Rev Immunol 25(5):353\u2013369","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2429_CR65","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala S, Hammer C, Delamarre L (2021) Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer 21(5):298\u2013312","journal-title":"Nat Rev Cancer"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02429-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-026-02429-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02429-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:09:59Z","timestamp":1789672199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-026-02429-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":65,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2429"],"URL":"https:\/\/doi.org\/10.1007\/s10495-026-02429-5","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"10 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures adhered to the ARRIVE guidelines and received approval from the Institutional Animal Ethics Committee of Xi\u2019an Jiaotong University (Ethical approval number: 2022-1123).","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"210"}}